The most effective group of drugs for the treatment of severe pain is opioid analgesics. Their use, however, is limited by decreased effects in neuropathic and chronic pain as a result of increased pain and development of tolerance. Gabapentin (GBP) is effective in both experimental models of chronic pain and clinical studies of neuropathic pain. Therefore, we investigated, in a randomized, placebo-controlled, double-blinded study, the pharmacodynamic and pharmacokinetic interaction of GBP and morphine in 12 healthy male volunteers. Morphine (60 mg, controlled release) or placebo was administered at 8:00 am, and GBP (600 mg) or placebo was administered at 10:00 am, thus comparing the analgesic effect of placebo ϩ GBP (600 mg) with placebo ϩ placebo and morphine (60 mg) ϩ GBP in comparison to morphine plus placebo by using the cold pressor test. The duration and intensity of the side effects were assessed by using visual analog scales. The analgesic effect was evaluated by the change in the area under the curve (h ϫ %; 0% baseline before Medication 1) of pain tolerance. Placebo ϩ GBP (18.9% ϫ h, 95% confidence interval [CI]: Ϫ2.5 to 40.3) did not present any significant analgesic effect compared with placebo ϩ placebo (4.7% ϫ h, 95% CI: Ϫ16.7 to 26.1). A significant increase in pain tolerance was observed comparing the combination of morphine and GBP (75.5% ϫ h, 95% CI: 54.0 -96.9) with morphine ϩ placebo (40.6% ϫ h, 95% CI:
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19.2-62.0). The observed adverse events after placebo ϩ GBP were not significantly different compared with placebo ϩ placebo. Morphine ϩ placebo led to the expected opioid-mediated side effects. They were significantly more pronounced compared with placebo ϩ placebo but did not differ significantly compared with the combination of morphine ϩ GBP. Concerning the pharmacokinetic variables of morphine and its glucuronides, no significant difference between morphine ϩ placebo and morphine ϩ GBP was observed, whereas the area under the curve of GBP (43.9 Ϯ 5.3 vs 63.4 Ϯ 16.2 g ⅐ h -1 ⅐ mL -1 , P Ͻ 0.05) significantly increased, and apparent oral clearance (230.8 Ϯ 29.4 mL/min vs 178 Ϯ 97.9 mL/min, P ϭ 0.06) and apparent renal clearance (86.9 Ϯ 20.6 vs 73.0 Ϯ 24.2 mL/min, P ϭ 0.067) of GBP decreased when morphine was administered concomitantly. These results suggest two different sites for the pharmacokinetic interaction-one at the level of absorption and the other at the level of elimination. Our study reveals both a pharmacodynamic and pharmacokinetic interaction between morphine and GBP, leading to an increased analgesic effect of morphine ϩ GBP. These results and the good tolerability of GBP should favor clinical trials investigating the clinical relevance of the combination of morphine and GBP for treating severe pain.
(Anesth Analg 2000;91:185-91) M orphine is the "gold standard" for treating severe pain. However, a major drawback of morphine is the need to increase the dose steadily, as a result of either increased pain or the developed tolerance (1). The use of opioids is limited both by side effects (such as sedation, nausea, vomiting, constipation, and respiratory depression) and by the fact that certain types of pain respond poorly to opioids (2) . As a consequence, opioid monotherapy may result in inadequate analgesia. Because a multiplicity of mechanisms are involved in pain (3), the limitations in the use of opioids can be overcome by combination therapy. Opioids are administered in combination with one or more nonopioid analgesics to obtain a more favorable balance of analgesia and side effects.
Gabapentin (GBP), a structural analog of ␥aminobutyric acid, is a novel anticonvulsant drug. Both clinical and experimental studies suggest that GBP has analgesic effects in neuropathic pain. GBP was shown to be effective in diabetic neuropathy (4) and postherpetic neuralgia (5) , whereas GBP was ineffective in transient animal pain models (6,7); however, it demonstrated analgesic activity in several animal models of postoperative (6) , neuropathic (8) , and inflammatory pain (7) . GBP enhanced the antinociceptive effect of spinal morphine in the rat tail-flick test (9) and preserved its analgesic effects in morphine-tolerant rats (6) .
Although GBP is not metabolized in humans and is excreted unchanged by glomerular filtration (10), most of morphine is transformed by phase II metabolism to morphine-3-glucuronide and the analgesic active morphine-6-glucuronide. Clinical studies have shown that GBP is a very safe and well tolerated drug (4, 5, 10) . Because of the good clinical tolerability of GBP and the synergistic effect of GBP concerning the analgesic action of morphine seen in animal experiments, we investigated the analgesic effects and pharmacokinetics of GBP and morphine in humans in an attempt to address the following questions: 1) Can GBP enhance the analgesic effect of morphine in humans using the cold pressor test? 2) Does GBP show an effect on its own in reducing the nociceptive pain provoked by the cold pressor test? 3) Is there a pharmacokinetic interaction between GBP and morphine? We therefore have performed a randomized, doubledummy, double-blinded study with cross-over design in healthy volunteers using the cold pressor test to assess the analgesic effects.
Methods
Twelve male volunteers were included in this study. They were healthy according to history, physical examination, and laboratory tests and did not take any medication. All volunteers gave their verbal and written informed consent before inclusion. The study had been approved by the ethics committee of the local medical board.
The study was designed as a randomized, doubledummy, double-blinded study with a four-way crossover design. Each volunteer received on the study Days 1, 8, 15, or 22 in random order (latin square design) two medications (8:00 and 10:00 am) 60 mg morphine sulfate (controlled release) ϩ GBP (600 mg), placebo ϩ GBP (600 mg), placebo ϩ placebo, or morphine sulfate (controlled release) ϩ GBP (600 mg) orally. The study Medication I and II was provided as identically appearing capsules by Pharmakapsel (Murr, Germany). The following identical procedure was conducted on study Days 1, 8, 15, and 22 : blood samples were taken before and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 24, and 25 h after drug administration. After 30 min, the samples were centrifuged, and serum was stored at Ϫ20°C. Urine was collected from 0 to 25 h, and an aliquot was stored at Ϫ20°C until analyzed.
The analgesic effects were assessed by using the cold pressor test as previously described (11) . The experiments were conducted on study Days 1, 8, 15, and 22 before drug administration and at 0.5, 1, 1.5, 2, 3, 3.5, 4, 5, and 6 h immediately after the blood sampling. Subsequently, for each study, the area under the pain tolerance-time curve was calculated by using pain tolerance data from 0 to 6 h corrected for the baseline at t ϭ 0 h.
For the documentation of the adverse effects, each symptom (somnolence, headache, dizziness, euphoria/ dysphoria, relaxation, blurred vision, nausea, pruritus, flush, dry mouth) was noted by the volunteers and rated on a visual analog scale (0 -10 points, 0 ϭ not present and 10 ϭ most severe) before and 2, 4, and 6 h after administration of Medication 1.
GBP concentrations in serum were determined by using high-performance liquid chromatography (HPLC) with UV detection (12) as follows. In brief, 0.5 mL of serum was mixed with internal standard (1-(aminomethyl)cycloheptaneacetic acid, Gö 3609) and deproteinized with perchloric acid. After derivatization with 2,4,6-trinitrobenzenesulfonic acid at pH 8.5, samples were extracted with toluene. The organic phase was evaporated with nitrogen and the residue dissolved in the mobile phase. HPLC separation was achieved on a Spherisorb ODS column (Waters, Millford, MA) with 5% acetic acid in water/acetonitrile 40:60 vol/vol as the mobile phase, the UV detector was set at 350 nm. GBP concentrations in urine (50 L) were determined after 1:10 dilution with water as described for serum, the deproteinization step was omitted.
Morphine and its metabolites morphine-3glucuronide and morphine-6-glucuronide in serum and urine have been determined with HPLCelectrospray mass spectrometry analogous to a previously published method (13) .
The maximum serum concentration (C max ) and the time point of C max were determined by visual inspection of the serum concentration-time curves. By using standard noncompartmental methods (TopFit 2.1; Gustav Fischer Verlag, Stuttgart, Germany), estimates of the area under the serum concentration-time curves (AUC) and terminal elimination half time of morphine and GBP were calculated by trapezoidal rule, and the segment to infinity was determined from the last concentration measured divided by the elimination rate constant. Apparent oral clearance (Cl o ) of morphine and GBP was calculated as dose/AUC. Ae represents the % of dose of urinary excreted (from 0 to 25 h) morphine, GBP, morphine-6-glucuronide, or morphine-3-glucuronide. Cl renal was calculated as Ae/AUC.
All data were presented as mean Ϯ sd. The pharmacokinetic data of morphine and its glucuronides and GBP after concomitant administration of morphine and GBP and administration of morphine or GBP alone were compared by using the paired t-test (Graphpad Instat 3.0, San Diego, CA). The measure of each side effect was obtained by calculating the sum of the three severity scores (2, 4, and 6 h). Further, the total side effect AUC 0 -6 h of each volunteer was calculated as the sum of all severity scores of the 10 different side effects registered (points ϫ h). Pharmacodynamic variables (pain threshold and pain tolerance) and side effects of the four treatment groups were compared by using a balanced two-way analysis of variance (ANOVA), with treatment and sequence of the subjects as factors and subsequent Fisher's exact test (Statgraphics, San Diego, CA). A P value of Ͻ0.05 was considered significant.
Results

Pharmacodynamic Results
In Figure 1A , pain tolerance-time curves of the four different treatments are presented as percentage of the baseline (0%) at t ϭ 0 h. Analysis of the corresponding area under pain tolerance-time curves showed a significant difference among the four treatment groups (P ϭ 0.05, two-way ANOVA). Post tests revealed significant differences between placebo ϩ placebo (4.7% ϫ h, 95% confidence interval [CI]: Ϫ16.7 to 26.1) compared with both morphine ϩ placebo (40.6% ϫ h, 95% CI: 19.2-62.0) and morphine ϩ GBP (75.5% ϫ h, 95% CI: 54.0 -96.9). No significant difference could be observed comparing placebo ϩ placebo and placebo ϩ GBP (18.9% ϫ h, 95% CI: Ϫ2.5 to 40.3). In combination with morphine however, a significant difference between placebo (morphine ϩ placebo) and GBP (morphine ϩ GBP) was observed.
Analysis of area under pain threshold-time curves (Fig. 1B) showed a significant difference among the four treatment groups (P ϭ 0.001, two-way ANOVA). Post tests revealed significant differences between morphine ϩ GBP (85.8% ϫ h, 95% CI: 54.0 -117.7) compared with both placebo ϩ placebo (11.0% ϫ h, 95% CI: Ϫ20.9 to 42.9) and placebo ϩ GBP (27.5% ϫ h, 95% CI: Ϫ4.3 to 59.4). No significant difference was observed between placebo ϩ placebo (11.0% ϫ h, 95% CI: Ϫ20.9 to 42.9) in comparison to placebo ϩ GBP (27.5% ϫ h, 95% CI: Ϫ4.3 to 59.4) and morphine ϩ placebo (54.5% ϫ h, 95% CI: 22.6 -86.3). In contrast to pain tolerance, no significant difference in pain threshold between morphine ϩ placebo and morphine ϩ GBP was observed. 
Pharmacokinetic Results
The serum concentration-time curves of morphine with and without GBP are presented in Figure 2A . The pharmacokinetics of morphine (AUC, C max , and Cl o ) were unchanged in the absence and presence of GBP (Table 1 ). In addition, no significant differences in pharmacokinetics of morphine-3-and morphine-6glucuronide were observed between morphine alone and morphine plus GBP ( Table 2) .
A significant increase of AUC (P ϭ 0.0004) was observed when morphine was administered concomitantly ( Fig. 2B , Table 1 ). C max (P ϭ 0.0788) and Ae (P ϭ 0.0732) of GBP increased in presence of morphine but did not reach statistical significance. In addition, there was a decrease of Cl o (P ϭ 0.0614) and Cl renal (P ϭ 0.0672) of GBP when morphine was administered concomitantly ( Fig. 2A, Table 1 ).
Side Effects
The most frequent side effects observed during the study were somnolence, dizziness, and nausea (four volunteers vomited on each morphine occasion). The sum (presented as mean Ϯ sd of 12 volunteers) of the AUC 0 -6 h of the registered side effects (somnolence, headache, dizziness, euphoria/dysphoria, relaxation, blurred vision, nausea, pruritus, flush, and dry mouth) after GBP ϩ placebo (15.9 Ϯ 10.2 points ϫ h) was not significantly different compared with placebo ϩ placebo (10.25 Ϯ 9.1 points ϫ h). As expected, a significant increase in the sum of the AUC 0 -6 h of side effects after morphine ϩ placebo (39.1 Ϯ 29.9 points ϫ h) could be observed in comparison to placebo ϩ placebo (P Ͻ 0.05) but was not significantly different compared with morphine ϩ GBP (48.2 Ϯ 29.9 points ϫ h; Figure 3 ).
Discussion
The results of our single-dose study investigating the acute analgesic effects of GBP alone and in combination with morphine in healthy volunteers by using the cold pressor test show that: 1) GBP has no analgesic effect on its own after a single oral dose of 600 mg in comparison to placebo; 2) GBP significantly enhances the analgesic effect of morphine; and 3) GBP pharmacokinetics, and not morphine pharmacokinetics, and metabolism are significantly altered when GBP and morphine are co-administered.
We administered morphine (60 mg) as a controlled release capsule to achieve a constant analgesic effect for four to six hours after morphine administration. GBP (600 mg) or placebo was administered two hours after morphine administration when a constant analgesic effect with morphine had just been achieved, thus allowing us to investigate the additional effect of GBP. The administered GBP dose of 600 mg is within the range of the doses (300 -800 mg) used to treat epilepsy and neuropathic pain (4, 5, 10) . Furthermore, pharmacokinetic studies demonstrated linear pharmacokinetics up to 600 mg whereas absorption decreased after the administration of larger doses. In addition, larger daily doses (2400 -3600 mg) require a titration phase because of initial central nervous system side effects. If the two drugs tested would present their maximal analgesic effects at different times, as observed for phenytoin (4.25 hours) and dihydrocodeine (1.25 hours) (14) , simultaneous administration might show analgesic effects that are difficult to interpret. The drug administration scheme we used allowed us to evaluate the additional analgesic effect of GBP for four hours. GBP in combination with morphine significantly enhanced pain tolerance compared with morphine plus placebo, whereas no significant increase in pain tolerance of GBP alone was observed in comparison with placebo. In addition, the pain threshold was increased after the administration of morphine ϩ GBP in comparison with morphine ϩ placebo.
The pharmacodynamic results of GBP are in agreement with data from animal experiments. GBP did not show any analgesic effect in transient pain models (tail-flick test) (6,7) but was effective only in different pain models with peripheral tissue damage or nerve lesions leading to hyperalgesia or allodynia (6 -8) . Thus, GBP and isobutylgaba have been designated as antihyperalgesic drugs. This might be explained by their effects in different pain models, which have shown that GBP and isobutylgaba reduced substance P, and N-methyl-d-aspartate (15) evoked hyperalgesia and reduced only the C fiber mediated phase II pain whereas A␤-fibers, reflecting acute pain, remained unaffected (7) . As the evoked pain during the cold pressor test we used was not accompanied by tissue damage or nerve lesions, the absence of an analgesic effect of GBP is not surprising. Other anticonvulsants were also investigated for their analgesic effects by using the cold pressor test. Lamotrigine and phenytoin presented a moderate, but significant, reduction in pain score compared with placebo, which was less pronounced than the effect of dihydrocodeine (14) . In combination with morphine, however, the same dose of GBP enhanced the analgesic effect of morphine significantly. The opioids display their action by binding to opioid receptors and opening G proteincoupled potassium channels and closing voltagedependent calcium channel, thus preventing the release of excitatory amino acids in the spinal cord (16) . The exact mode of action of GBP is still unknown. Besides its effects on excitatory (glutamate) and inhibitory ␥-aminobutyric acid amino acids (17) , binding to the ␣ 2 ␦ subunit of calcium channels has been observed (18) . Thus, GBP might modulate release of excitatory amino acids in the dorsal horn of the spinal cord (17) . L-type calcium channel blockers have also been investigated for their analgesic effects when administered alone and in combination with morphine. However, the calcium antagonists verapamil, diltiazem, and nitrendipine did not demonstrate any analgesic effect alone or in combination with morphine in healthy volunteers (19) , whereas nimodipine decreased the morphine dose in morphine-tolerant cancer patients with severe pain (20) . Both experimental and clinical data, therefore, suggest different mechanisms by which GBP and L-type calcium channel blockers mediate their analgesic effects. Further investigations are necessary to elucidate the exact mode of action of GBP.
Concerning the pharmacokinetic data (AUC, C max , Cl o , and terminal elimination half time), no significant difference was observed for morphine and its glucuronides after concomitant administration of GBP, as compared with placebo. The observed enhancement of morphine analgesia by GBP is therefore not a result of a pharmacokinetic interaction to larger morphine and/or morphine glucuronide concentrations. In contrast, the pharmacokinetics (AUC, C max , and Ae) of GBP were altered when morphine was administered simultaneously. GBP AUC increased by 44%, the amount of GBP excreted in urine (Ae) increased by 25%, and therefore, the renal clearance of GBP decreased only slightly during concomitant morphine administration. These changes in GBP pharmacokinetics could be a result of increased absorption caused by reduced intestinal motility.
We observed a pharmacokinetic and pharmacodynamic interaction. In animal experiments, a significant pharmacodynamic interaction was postulated, as the dose-response curve of morphine was shifted to the left (9) . The increased analgesic effect after the administration of morphine plus GBP in our study might be the consequence of a pharmacodynamic interaction as the morphine concentration was not affected by GBP, and GBP did not show a significant analgesic effect when administered alone. An influence of the increased serum concentration of GBP, when administered in combination with morphine, on the increased analgesic effect of the combination cannot be excluded and should be considered in further studies.
Some chronic pain states, such as neuropathic pain, respond poorly to opioids (2) . Neuropathic pain and morphine tolerance have shown similar mechanisms in animal experiments, such as activation of N-methyld-aspartate receptors, activation of protein kinase C (21), induction of immediate early genes (c-fos, c-jun) (22) and nitric oxide synthase (21) , and increased binding sites of dihydropyridine, linked to L-type calcium channels (23) . As a consequence of this better understanding of the mechanisms involved in morphine tolerance and chronic pain, clinical investigations of morphine in combination with drugs preventing/ reducing morphine tolerance or retaining their analgesic effects under morphine tolerance are required. GBP has shown antihyperalgesic effects both in several models of chronic pain and in patients who have chronic pain (4, 5, 7, 8) . Furthermore, GBP has increased the analgesic effect of morphine in morphine-naive as well as in morphine-tolerant rats (6, 9) . In our study, it could also be observed for the first time in humans that GBP enhanced the analgesic effect of morphine in nociceptive pain evoked by the cold pressor test.
These preclinical and clinical results support the clinical investigation of morphine/GBP in the treatment of chronic pain, which responds poorly to opioids. This is particularly true because GBP has substantial advantages concerning pharmacokinetics, safety, and tolerability in comparison with the established anticonvulsants, as their clinical use is often limited by a small therapeutic range and several drug interactions (24) . GBP is not metabolized in humans, is not protein-bound, is exclusively excreted by glomerular filtration, and does not present any relevant drug interactions (10) . Clinically, GBP is well tolerated and does not show any relevant acute and chronic toxicity (10) . The results of our study and the favorable profile, especially in comparison with other anticonvulsants, should support the clinical investigation of the additional administration of GBP in patients suffering severe and chronic pain and treated with morphine. Especially in these patients, the additional analgesic effect of GBP should be more pronounced than in healthy volunteers, considering the above mentioned data from various pain models in animals. Thus, a combination of GBP and morphine should result both in better pain control, including types of pain that respond poorly to opioids, and in a decrease in morphine dose and, consequently, a decrease in opioidmediated adverse reactions (constipation, respiratory depression).
The enhanced analgesic effect of morphine resulting from the additional administration of GBP shown in our study has been confirmed in a recently published clinical study (25) . The combination of morphine plus GBP demonstrated better analgesia in patients suffering neuropathic cancer pain in comparison with morphine alone. Further controlled trials in patients who have acute or chronic pain are necessary to investigate the efficacy, tolerability, and safety of this drug combination compared with morphine alone.
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